Article info

Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures

Authors

  • Laurene S Cheung Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Lingling Chen Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Teniola F Oke Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Thomas B Schaffer NextCure Inc, Beltsville, Maryland, USA PubMed articlesGoogle scholar articles
  • Karim Boudadi Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Jillian T Ngo Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • John McMahon Gross Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Holly Kemberling Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Luis A Diaz Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Evan Lipson Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • John-WIlliam Sidhom Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Janis Taube Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Robert Anders Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Drew M Pardoll Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Dung T Le Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Christian F Meyer Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Nicolas Llosa Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Nicolas Llosa; nllosa1{at}jhmi.edu
View Full Text

Citation

Cheung LS, Chen L, Oke TF, et al
Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures

Publication history

  • Accepted April 18, 2021
  • First published June 8, 2021.
Online issue publication 
June 08, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.